Member Info for Mars1

Could be fun not the main course

If these guys raise $53m it is 3x value of NFX they are not playing a game of soldiers

$73bn
https://www.grandviewresearch.com/press-release/global-legal-marijuana-market

Sorry $73bn market is not worth it. 20% of $1bn (1.5%) = 200m conservative p/e 10 =$2bn

Must be ready as they now need $53m to get going

Should be a great return for NFX if it is right

Ebers 80%, NFX 20% DT wins both ways but North American quote and return looks an attractive ratio

That can only mean Ebers have manufacturing contracts and distribution lined up for the products ready to go

So DT raising cash for the private placement to take as much a launch share as possible

RNS 9/19 “ The patented cannabinoid forms have immediate applications in both pharmaceutical and consumer products worldwide, which in due course, will generate further milestone payments, plus royalties to Nuformix of 20% under the Agreement terms.”

MHRA probably do not trust the public to understand the difference between antigen and antibody tests, so only antigen tests are being approved atm.

So if we have a deal on the table question is have all requirements being met and are we now just waiting for counterparty bod approval. Or could we be waiting for the results of the latest study or is this just extra support information for further deal discussions.
“ Pre-clinical development activities were prioritised to evaluate the benefits of NXP002 alone and in combination with standard of care for the treatment of IPF. Results of this study are expected in the first quarter of 2021.”
The first results from Newcastle seemed pretty conclusive however Kissei have tried to outsource another Tranilast development which did not progress so they may being extra cautious therefore the additional study data may help.

Seeing more buys than sells, old economics should still apply at some point, not moaning, pointing out facts.

Feeble sells for a few hundred pounds results in the price drop

Lot of competition for these grants, last year were awarded on 20/2 although Govt paper of award results not out until mid April when the grant spending was already well underway . Further testing planned for NXP002 could be Ards could be covid or IPF

Four days into the post Xmas break hardly time to get breath if recruiting more shift supervisors, wondered if they have cleared all those Mologic boxes.

Soup yes could be a rational explanation but deal is also rather ‘done’ (as in done deal)rather than liscensing opportunities

Cannot believe that type of error would be made in an RNS

Not if it is conditional as it is not a live deal until conditions are met and cannot if subject to an NDA.

This is from the RNS of 7th October, is this tardy wording or is NFX subject to an NDA until certain conditions are met?
“ The Board believes that the Net Placing Proceeds will optimise the Group's chances to secure additional licensing deals.”
Notice it says secure additional license deals which means there is at least one in the bag, or is it tardy English?